Latest Oncology News

Efficacy of Mobocertinib Lowered by Dose Reductions in EGFR+ NSCLC

January 18, 2022

Danny Nguyen, MD, discusses an analysis of efficacy and adverse events of mobocertinib in patients with EGFR-positive non–small cell lung cancer that was presented at the European Society for Medical Oncology 2021 Congress.

FDA Grants Fast Track Designation to CYNK-101 for HER2+ Gastric/GEJ Cancers

January 18, 2022

A fast track designation has been granted to CYNK-101 in combination with standard frontline chemotherapy, trastuzumab, and pembrolizumab for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

BTK Inhibitors Continue to Offer Chemotherapy-Free Options for MCL Treatment

January 18, 2022

At the 63rd ASH Annual Meeting and Exposition, studies highlighted the promise of Bruton's tyrosine kinase inhibitors for the treatment of patients with mantle cell lymphoma and what oncologists should do after Bruton's tyrosine kinase inhibition.

FDA Grants Priority Review to Fam-Trastuzumab Deruxtecan-Nxki for HER2+ mBC

January 17, 2022

The FDA has accepted a supplement biologics license application for fam-trastuzumab deruxtecan-nxki and granted it priority review for the treatment of adult patients with unresectable or HER2-positive metastatic breast cancer who have received a prior anti-HER2- based regimen.

Roundtable Discussion: Pagel Walks Through Treatment Choices in Chronic Lymphocytic Leukemia

January 16, 2022

During a Targeted Oncology live event, John M. Pagel, MD, PhD, and participants discussed their experiences with BTK inhibitors such as acalabrutinib and ibrutinib in terms of efficacy and tolerability as well as other treatment options in patients with chronic lymphocytic leukemia.